REG - Physiomics PLC - AIM Rule 17 and Schedule 2(g) Update

PhysiomicsAnnouncement

Wed 17:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250507:nRSG7560Ha&default-theme=true

RNS Number : 7560H  Physiomics PLC  07 May 2025

7 May 2025

 

Physiomics plc

("Physiomics" or the "Company")

 

Update re: AIM Rule 17 - Schedule Two (g) Director's Disclosure

 

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and
biostatistics company supporting the development of new therapeutics and
personalised medicine solutions, provides the following update in accordance
with AIM Rule 17 and Schedule Two(g) sub-paragraph (v) of the AIM Rules for
Companies:

Dr. Timothy Corn, a Non-Executive Director of the Company, is an Executive
Director of Oxford Cannabinoid Technologies Holdings plc ("OCT"), a public
company incorporated in England and Wales, having been appointed to this role
in November 2023. On 2 May 2025, OCT was placed into administration.

 

For more information about Physiomics and its services, please visit
www.physiomics.co.uk (http://www.physiomics.co.uk) .

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep biology
expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and optimise
research design across discovery, pre-clinical and clinical studies. Through
use of cutting-edge computational tools, bespoke models and our proprietary
Virtual Tumour technology, the Physiomics team has informed the development of
over 100 commercial projects, with over 125 targets and drugs modelled.
Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK. 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDARMATMTIMBJA